GoHealth (GOCO) Stock Price, News & Analysis

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GoHealth in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GOCO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GOCO, but not buy additional shares or sell existing shares.
View GOCO analyst ratings or view top-rated stocks.

1 brokerages have issued 1 year price targets for GoHealth's stock. Their GOCO share price targets range from $13.00 to $13.00. On average, they expect the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 23.8% from the stock's current price.
View analysts price targets for GOCO or view top-rated stocks among Wall Street analysts.

GoHealth's stock was trading at $13.34 at the beginning of the year. Since then, GOCO stock has decreased by 21.3% and is now trading at $10.50.
View the best growth stocks for 2024 here.

GoHealth saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 223,400 shares, an increase of 8.9% from the March 15th total of 205,100 shares. Based on an average daily volume of 15,000 shares, the days-to-cover ratio is presently 14.9 days. Currently, 3.0% of the company's shares are short sold.
View GoHealth's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GOCO earnings forecast.

GoHealth will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

GoHealth, Inc. (NASDAQ:GOCO) issued its quarterly earnings results on Thursday, March, 14th. The company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.73 by $2.13. The company earned $276.70 million during the quarter, compared to the consensus estimate of $362.38 million. GoHealth had a negative net margin of 8.61% and a negative trailing twelve-month return on equity of 9.29%.

25 employees have rated GoHealth Chief Executive Officer Matthew Crummack on Glassdoor.com. Matthew Crummack has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other GoHealth investors own include Tesla (TSLA), Alibaba Group (BABA), CVS Health (CVS), Moderna (MRNA), RTX (RTX), Walmart (WMT), Cisco Systems (CSCO), Intel (INTC) and Johnson & Johnson (JNJ).

GoHealth (GOCO) raised $750 million in an initial public offering on Wednesday, July 15th 2020. The company issued 39,500,000 shares at $18.00-$20.00 per share. Goldman Sachs, BofA Securities and Morgan Stanley served as the underwriters for the IPO and Barclays, Credit Suisse, Evercore ISI, RBC Capital Markets, William Blair, Cantor, SunTrust Robinson Humphrey and Loop Capital Markets were co-managers.

Shares of GOCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.